First Line Chemotherapy for Advanced Cancer
The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Cancer
DRUG: albumin-bounded paclitaxel|DRUG: S-1
response rate, 12 weeks
progression free survival, 1 year|overall survival, 1 year|number of adverse event, 1 year
This phase II study was designed to evaluate the efficacy and safety of albumin-bounded paclitaxel combined with S-1 as first-line chemotherapy for inoperable and /or metastatic gastric or gastroesophageal junction cancer.Primary endpoint was overall response rate.